DocWire News Editors

DocwireNews

Researchers often struggle to find the right participants for their clinical trials. Many studies have very specific requirements, and it is imperative that these studies not only enroll enough participants but that these volunteers meet the proper inclusion criteria as well. To facilitate the recruitment process in clinical trials, researchers from the Cincinnati Children&rsquo;s Hospital Medical Center have recently created an<a href="https://www.docwirenews.com/docwire-pick/future-of-medicine-picks/artificial-intelligence-system-able-to-differentiate-types-of-cancer-cells/"> artificial intelligence (AI)</a> platform that identifies eligible patients for trials based on Electronic Health Records (EHRs). Their work was published in <a href="https://medinform.jmir.org/2019/3/e14185/">JMIR Medical Informatics</a>. Lead investigator Yizhao Ni, Ph.D., claims that their AI system, the Automated Clinical Trial Eligibility Screener (ACTES), leverages EHR data to rapidly screen potential candidates. Though traditional methods of recruiting participants in busy medical environments such as the emergency department have been effective, they don&rsquo;t always recruit enough individuals.&ldquo;Because of the large volume of data documented in EHRs, the recruiting processes used now to find relevant information are very labor-intensive within the short time frame needed,&rdquo; said Ni. &ldquo;By leveraging natural language processing and <a href="https://www.docwirenews.com/abstracts/machine-learning-guided-directed-evolution-for-protein-engineering/">machine learning</a> technologies, ACTES was able to quickly analyze different types of data and automatically determine patients&rsquo; suitability for clinical trials.&rdquo;<h2>Technology Behind AI Technology</h2>ACTES functions using natural language processing, enabling it to comprehend human language as it analyzes a vast amount of data. The system rapidly extracts information such as patient demographics and other statistics from EHRs to compare to the set inclusion criteria for a given clinical trial. This advanced AI also pulls unstructured information from the physician&rsquo;s clinical notes as well, including symptoms, treatments, and diagnoses.The AI is also equipped with machine learning capabilities that allow it to automatically learn and improve its processes over time without further programming. This component also enables ACTES to learn from previous trial enrollments to enhance its selection skills using AI algorithms.<h2>Background of the ACTES Study</h2>ACTES was previously tested in a retrospective study published in 2015, but this new research evaluated the system in real-time within a busy emergency department. This was done at the pediatric emergency department at Cincinnati Children&rsquo;s Hospital Medical Center. ACTES continuously analyzed EHR data for these patients and recommended them for any of six potential clinical trials. Patient eligibility data was presented to the personnel in charge of the clinical trials in real-time on a dashboard.This study found that compared to the manual screening process, ACTES cut patient screening time down by 34% in the recruitment process. In addition, patient enrollment increased by 11.1%, the number of patients screened by 14.7%, and the number of patients approached by 11.1%.This use of this AI in the clinical environment required collaboration between the research scientists, software developers, information technicians, and the clinical staff.&ldquo;Thanks to the institution&rsquo;s collaborative environment, we successfully incorporated different groups of experts in designing the integration process of this AI solution,&rdquo; Ni concluded.The researchers noted that a limitation to the study is that it only recruited patients from one center for a small number of different trials. It could become more challenging for ACTES to identify potential candidates if the number of clinical trials it had to match increased. Ni and colleagues also noted several issues regarding the system&rsquo;s accuracy in interpreting data, but they claim these issues will be resolved in future studies.<blockquote class="twitter-tweet">
It takes 10-15 years and costs between $1.5-$2.0 billion to bring a new <a href="https://twitter.com/hashtag/drug?src=hash&amp;ref_src=twsrc%5Etfw">#drug</a> to market, and half of this <a href="https://twitter.com/hashtag/capital?src=hash&amp;ref_src=twsrc%5Etfw">#capital</a> is dedicated to <a href="https://twitter.com/hashtag/clinicaltrials?src=hash&amp;ref_src=twsrc%5Etfw">#clinicaltrials</a>. <a href="https://twitter.com/hashtag/AI?src=hash&amp;ref_src=twsrc%5Etfw">#AI</a> tools have emerged as a viable way to increase clinical trial success rates, researchers said.<a href="https://t.co/uZmWV2SAKj">https://t.co/uZmWV2SAKj</a>
&mdash; Chasm Partners (@ChasmPartners) <a href="https://twitter.com/ChasmPartners/status/1154047704852381696?ref_src=twsrc%5Etfw">July 24, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Using AI to Better Recruit Clinical Trial Participants

Researchers often struggle to find the right participants for their clinical trials. Many studies have very specific requirements, and it is imperative that these studies not ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe